Imax saw its IBD SmartSelect Composite Rating rise to 97 Friday, up from 90 the day before.
Lean How — And When — To Sell Stocks
The new score tells you the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
Imax is not currently near a proper entry. See if the stock goes on to form a new base and offer a new buying opportunity.
The stock has an 89 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 89% of all stocks.
Its Accumulation/Distribution Rating of C- shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
In Q1, the company reported -13% EPS growth. Sales growth increased 10%, up from 8% in the prior report. The company has now posted rising growth in each of the last two quarters.
Imax earns the No. 3 rank among its peers in the Leisure-Movies & Related industry group. Netflix is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
